Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,466 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of Danlou tablets in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a multicenter prospective cohort study.
Cai Y, Yang Q, Xi R, Yang F, Gu F, Zhao Y, Guo M, Dong G, Gao Z, Fu C, Wang P, Du J, Zhang D, Duan W, Li L, Shi D, Bai R. Cai Y, et al. Among authors: duan w. Front Cardiovasc Med. 2024 Sep 24;11:1420194. doi: 10.3389/fcvm.2024.1420194. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39380631 Free PMC article.
The effectiveness and safety of Chinese Patent Medicines based on syndrome differentiation in patients following percutaneous coronary intervention due to acute coronary syndrome (CPM trial): A nationwide Cohort Study.
Bai R, Yang Q, Xi R, Che Q, Zhao Y, Guo M, Dong G, Gao Z, Fu C, Wang P, Gu F, Du J, Zhang D, Duan W, Li L, Shi D. Bai R, et al. Among authors: duan w. Phytomedicine. 2023 Jan;109:154554. doi: 10.1016/j.phymed.2022.154554. Epub 2022 Nov 19. Phytomedicine. 2023. PMID: 36610159 Free article. Clinical Trial.
P2y12 inhibitor monotherapy after 1-3 months dual antiplatelet therapy in patients with coronary artery disease and chronic kidney disease undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
Yu Y, Pan D, Bai R, Luo J, Tan Y, Duan W, Shi D. Yu Y, et al. Among authors: duan w. Front Cardiovasc Med. 2023 Jul 6;10:1197161. doi: 10.3389/fcvm.2023.1197161. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37485257 Free PMC article. Review.
Effectiveness and Safety of Qishen Yiqi Dripping Pill in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: 3-Year Results from a Multicentre Cohort Study.
Bai RN, Gu F, Che QZ, Zhang X, Cai YJ, Xi RX, Zhao Y, Guo M, Dong GJ, Gao ZY, Fu CG, Wang PL, Du JP, Zhang DW, Duan WH, Li LZ, Yang QN, Shi DZ. Bai RN, et al. Chin J Integr Med. 2024 Oct;30(10):877-885. doi: 10.1007/s11655-024-3664-1. Epub 2024 Aug 21. Chin J Integr Med. 2024. PMID: 39172302
Combination of Activating Blood Circulation and Detoxifying Chinese Medicines Played an Anti-Inflammatory Role in Unstable Angina Patients after Percutaneous Coronary Intervention: A Multicenter, Open-Labeled, Randomized Controlled Trial.
Ma XJ, Duan WH, Zhang Y, Gao J, Guan BY, Chen KJ, Shi DZ. Ma XJ, et al. Chin J Integr Med. 2021 Nov;27(11):803-810. doi: 10.1007/s11655-021-2878-8. Epub 2021 Sep 16. Chin J Integr Med. 2021. PMID: 34532749 Clinical Trial.
Quanduzhong capsules for the treatment of grade 1 hypertension patients with low-to-moderate risk: A multicenter, randomized, double-blind, placebo-controlled clinical trial.
Xu X, Tian W, Duan W, Pan C, Huang M, Wang Q, Yang Q, Wen Z, Tang Y, Xiong Y, Zhu Z, Liu Y, Wei D, Qi W, Ouyang X, Ying S, Wang X, Zhou Z, Li X, Cui Y, Yang S, Xu H. Xu X, et al. Among authors: duan w. Front Pharmacol. 2023 Jan 10;13:1014410. doi: 10.3389/fphar.2022.1014410. eCollection 2022. Front Pharmacol. 2023. PMID: 36703729 Free PMC article.
3,466 results